Inbec是治什么的？

Trimax () is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50mg, abacavir sulfate (calculated as abacavir) 600mg and lamivudine 300mg. It is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a weight of at least 40kg).

Existing research shows that one year (48 weeks) after treatment with Inbec, 93% of HIV-infected patients turned negative.

The recommended dosage of Inbec is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Inbec because Inbec is a fixed-dose tablet and the dose cannot be reduced. Regardless of patient race, patients should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B*5701 allele, he should not take products containing abacavir.

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. Patients whose creatinine clearance is less than 50 mL/min are not recommended to take this product. Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

In 2018, GlaxoSmithKline (GSK) announced that its controlled joint venture ViiV Healthcare's single-pill compound preparation Suimeikai (), which is based on the new generation integrase inhibitor Tevicai (dolutegravir), for the treatment of HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.